Company Filing History:
3 out of 4,872 
1 out of 1 Years Active: 2017-2021
Title: The Innovative Contributions of Inventor Mathieu Charveriat
Introduction
Mathieu Charveriat, a distinguished inventor based in Issy les Moulineaux, France, has made significant strides in the field of pharmacology through his innovative approach to psychiatric and neurodegenerative disorder treatments. With a total of three patents to his name, Charveriat's work reflects a commitment to enhancing therapeutic methodologies that improve patient outcomes.
Latest Patents
Charveriat's latest patents showcase his expertise in the use of anti-connexin agents to enhance the effectiveness of psychotropic drugs. One notable invention relates to the use of connexin-blocking agents combined with psychotropic medications, providing flexible treatment approaches for patients suffering from psychiatric and neurodegenerative disorders. Specifically, the patented product includes agents such as meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, with a preference for meclofenamic acid.
Another crucial invention addresses the neurological treatments employing acetylcholinesterase inhibitors, highlighting the potential of connexin-blocking agents to amplify the effects of the reversible acetylcholinesterase inhibitor donepezil. This synergy represents a significant advancement in therapeutic strategies for neurological and neuropsychic conditions.
Career Highlights
Throughout his career, Mathieu Charveriat has worked with esteemed organizations such as the Commissariat à l'Énergie Atomique et aux Énergies Alternatives and Bio Modeling Systems (BMSystems). His tenure at these institutions has enabled him to collaborate on pivotal projects that push the boundaries of medical science and improve therapeutic options available to patients.
Collaborations
Charveriat's innovative journey is complemented by collaborations with notable colleagues such as Franck Mouthon and Jean-Philippe Deslys. These partnerships have fostered an environment of creativity and shared knowledge, contributing to the advancements realized in his patents.
Conclusion
Mathieu Charveriat stands out as an influential inventor in the realm of pharmacological innovations. His latest patents and collaborative efforts with industry leaders reflect a strong dedication to improving therapeutic applications for patients with challenging neurodegenerative and psychiatric disorders. As his work continues to evolve, it promises to pave the way for further advancements in medical treatments that could benefit countless individuals worldwide.